440 related articles for article (PubMed ID: 1531076)
1. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
2. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
[TBL] [Abstract][Full Text] [Related]
4. Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.
Manning M; Kruszynski M; Bankowski K; Olma A; Lammek B; Cheng LL; Klis WA; Seto J; Haldar J; Sawyer WH
J Med Chem; 1989 Feb; 32(2):382-91. PubMed ID: 2913298
[TBL] [Abstract][Full Text] [Related]
5. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
6. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Kolodziejczyk AM; Seto J; Sawyer WH
J Med Chem; 1981 Jun; 24(6):701-6. PubMed ID: 7252979
[TBL] [Abstract][Full Text] [Related]
7. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
8. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
Manning M; Cheng LL; Klis WA; Balaspiri L; Olma A; Sawyer WH; Wo NC; Chan WY
J Med Chem; 1995 May; 38(10):1762-9. PubMed ID: 7752199
[TBL] [Abstract][Full Text] [Related]
9. Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.
Manning M; Stoev S; Kolodziejczyk A; Klis WA; Kruszynski M; Misicka A; Olma A; Wo NC; Sawyer WH
J Med Chem; 1990 Nov; 33(11):3079-86. PubMed ID: 2231609
[TBL] [Abstract][Full Text] [Related]
10. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.
Manning M; Przybylski J; Grzonka Z; Nawrocka E; Lammek B; Misicka A; Cheng LL; Chan WY; Wo NC; Sawyer WH
J Med Chem; 1992 Oct; 35(21):3895-904. PubMed ID: 1433200
[TBL] [Abstract][Full Text] [Related]
11. Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.
Manning M; Klis WA; Kruszynski M; Przybylski JP; Olma A; Wo NC; Pelton GH; Sawyer WH
Int J Pept Protein Res; 1988 Dec; 32(6):455-67. PubMed ID: 3246475
[TBL] [Abstract][Full Text] [Related]
12. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
13. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.
Manning M; Olma A; Klis WA; Kolodziejczyk AM; Seto J; Sawyer WH
J Med Chem; 1982 Jan; 25(1):45-50. PubMed ID: 7086821
[TBL] [Abstract][Full Text] [Related]
14. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.
Manning M; Nawrocka E; Misicka A; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1984 Apr; 27(4):423-9. PubMed ID: 6708045
[TBL] [Abstract][Full Text] [Related]
15. Design of potent antagonists of the vasopressor response to arginine-vasopressin.
Bankowski K; Manning M; Haldar J; Sawyer WH
J Med Chem; 1978 Sep; 21(9):850-3. PubMed ID: 722751
[TBL] [Abstract][Full Text] [Related]
16. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
Manning M; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
Manning M; Miteva K; Pancheva S; Stoev S; Wo NC; Chan WY
Int J Pept Protein Res; 1995; 46(3-4):244-52. PubMed ID: 8537178
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and receptor specificities of vasopressin antagonists.
Manning M; Sawyer WH
J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S29-35. PubMed ID: 2434768
[TBL] [Abstract][Full Text] [Related]
19. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists.
Ferris CF; Singer EA; Meenan DM; Albers HE
Eur J Pharmacol; 1988 Sep; 154(2):153-9. PubMed ID: 2976377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
